Literature DB >> 19028449

Antimicrobial peptide mimics for improved therapeutic properties.

Shahar Rotem1, Amram Mor.   

Abstract

The relatively recent recognition of the major role played by antimicrobial peptides (AMPs) in sustaining an effective host response to immune challenges was greatly influenced by studies of amphibian peptides. AMPs are also widely regarded as a potential source of future antibiotics owing to a remarkable set of advantageous properties ranging from molecular simplicity to low-resistance swift-kill of a broad range of microbial cells. However, the peptide formula per se, represents less than ideal drug candidates, namely because of poor bioavailability issues, potential immunogenicity, optional toxicity and high production costs. To address these issues, synthetic peptides have been designed, reproducing the critical peptide biophysical characteristic in unnatural sequence-specific oligomers. Thus, the use of peptidomimetics to overcome the limitations inherent to peptides physical characteristics is becoming an important and promising approach for improving the therapeutic potential of AMPs. Here, we review most recent advances in the design strategies and the biophysical properties of the main classes of mimics to natural AMPs, emphasizing the importance of structure-activity relationship studies in fine-tuning of their physicochemical attributes for improved antimicrobial properties.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19028449     DOI: 10.1016/j.bbamem.2008.10.020

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  79 in total

1.  Effect of proline position on the antimicrobial mechanism of buforin II.

Authors:  Yang Xie; Eleanor Fleming; Jessica L Chen; Donald E Elmore
Journal:  Peptides       Date:  2011-01-26       Impact factor: 3.750

Review 2.  Cationic amphiphiles, a new generation of antimicrobials inspired by the natural antimicrobial peptide scaffold.

Authors:  Brandon Findlay; George G Zhanel; Frank Schweizer
Journal:  Antimicrob Agents Chemother       Date:  2010-08-09       Impact factor: 5.191

3.  Experimental conditions that enhance potency of an antibacterial oligo-acyl-lysyl.

Authors:  Yair Goldfeder; Fadia Zaknoon; Amram Mor
Journal:  Antimicrob Agents Chemother       Date:  2010-04-12       Impact factor: 5.191

4.  Mechanisms mediating bactericidal properties and conditions that enhance the potency of a broad-spectrum oligo-acyl-lysyl.

Authors:  Hadar Sarig; Yair Goldfeder; Shahar Rotem; Amram Mor
Journal:  Antimicrob Agents Chemother       Date:  2010-11-15       Impact factor: 5.191

Review 5.  Nontraditional therapies to treat Helicobacter pylori infection.

Authors:  Morris O Makobongo; Jeremy J Gilbreath; D Scott Merrell
Journal:  J Microbiol       Date:  2014-03-29       Impact factor: 3.422

6.  Antibacterial properties and mode of action of a short acyl-lysyl oligomer.

Authors:  Fadia Zaknoon; Hadar Sarig; Shahar Rotem; Liran Livne; Andrey Ivankin; David Gidalevitz; Amram Mor
Journal:  Antimicrob Agents Chemother       Date:  2009-06-01       Impact factor: 5.191

7.  Activity of antimicrobial peptide mimetics in the oral cavity: I. Activity against biofilms of Candida albicans.

Authors:  J Hua; R Yamarthy; S Felsenstein; R W Scott; K Markowitz; G Diamond
Journal:  Mol Oral Microbiol       Date:  2010-12       Impact factor: 3.563

8.  Rationale-based, de novo design of dehydrophenylalanine-containing antibiotic peptides and systematic modification in sequence for enhanced potency.

Authors:  Sarika Pathak; Virander Singh Chauhan
Journal:  Antimicrob Agents Chemother       Date:  2011-02-14       Impact factor: 5.191

9.  A miniature mimic of host defense peptides with systemic antibacterial efficacy.

Authors:  Hadar Sarig; Liran Livne; Victoria Held-Kuznetsov; Fadia Zaknoon; Andrey Ivankin; David Gidalevitz; Amram Mor
Journal:  FASEB J       Date:  2010-02-02       Impact factor: 5.191

Review 10.  The roles of antimicrobial peptides in innate host defense.

Authors:  Gill Diamond; Nicholas Beckloff; Aaron Weinberg; Kevin O Kisich
Journal:  Curr Pharm Des       Date:  2009       Impact factor: 3.116

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.